In a report released on February 12, Justine Telliez from Kepler Capital maintained a Buy rating on Valneva (0OB3 – Research Report), with a ...
ADRs traded higher in the premarket on Tuesday after the French biotech posted additional data for its FDA-approved chikungunya vaccine, Ixchiq, from a Phase 3 trial for people aged 12–17 years old in ...
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the signing of a new $32.8 million contract with the United States (U.S.) Department of Defense (DoD) for ...
Valneva's Ixchiq is the first and only approved Chikungunya vaccine in the US, Canada, and EU. Ixiaro is for Japanese encephalitis, and it’s today VALN’s main revenue contributor. But its near ...
24d
GlobalData on MSNValneva announces positive outcomes from chikungunya vaccine trialValneva has announced positive outcomes from its Phase III VLA1553-321 trial of the single-shot IXCHIQ chikungunya virus (CHIKV) vaccine in adolescents.
While much of Valneva's focus these days is centered on its landmark vaccine for chikungunya virus, the French immunization specialist's catalog of older shots continues to serve up fresh governmen | ...
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Valneva’s single-dose chikungunya vaccine for use ...
H.C. Wainwright reaffirmed its Buy rating and $18.00 price target for Valneva (EPA:VLS) SE (NASDAQ:VALN) shares, following the recent approval of the company's Ixchiq vaccine in the United Kingdom ...
8d
GlobalData on MSNValneva’s chikungunya vaccine wins UK approvalValneva’s chikungunya vaccine Ixchiq has been greenlit by the UK’s MHRA, allowing the single-dose vaccine to be made ...
VALNEVA Declaration of shares and voting rights January 31, 2025_____ Company name: VALNEVARegistered office ...
Valneva has recieved Medicines and Healthcare products Regulatory Agency (MHRA) authorisation in the UK for the world’s first - and only - Chikungunya vaccine, IXCHIQ. The single-dose vaccine is ...
Saint Herblain (France), February 5, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the Medicines and Healthcare products Regulatory ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results